MODRASTANE Drug Patent Profile
✉ Email this page to a colleague
When do Modrastane patents expire, and when can generic versions of Modrastane launch?
Modrastane is a drug marketed by Bioenvision and is included in one NDA.
The generic ingredient in MODRASTANE is trilostane. There are two drug master file entries for this compound. Additional details are available on the trilostane profile page.
Summary for MODRASTANE
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 92 |
Patent Applications: | 6,903 |
Formulation / Manufacturing: | see details |
DailyMed Link: | MODRASTANE at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for MODRASTANE
US Patents and Regulatory Information for MODRASTANE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioenvision | MODRASTANE | trilostane | CAPSULE;ORAL | 018719-002 | Dec 31, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Bioenvision | MODRASTANE | trilostane | CAPSULE;ORAL | 018719-001 | Dec 31, 1984 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |